- Home
- VIVS vs IDAI Comparison
VIVS vs IDAI Comparison
Compare VIVS & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- IDAI
- Stock Information
- Founded
- VIVS 2007
- IDAI 2016
- Country
- VIVS United States
- IDAI United States
- Employees
- VIVS N/A
- IDAI N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- IDAI Computer Software: Prepackaged Software
- Sector
- VIVS Health Care
- IDAI Technology
- Exchange
- VIVS Nasdaq
- IDAI Nasdaq
- Market Cap
- VIVS 4.6M
- IDAI 4.9M
- IPO Year
- VIVS N/A
- IDAI N/A
- Fundamental
- Price
- VIVS $1.77
- IDAI $2.71
- Analyst Decision
- VIVS
- IDAI
- Analyst Count
- VIVS 0
- IDAI 0
- Target Price
- VIVS N/A
- IDAI N/A
- AVG Volume (30 Days)
- VIVS 53.7K
- IDAI 29.0K
- Earning Date
- VIVS 08-12-2025
- IDAI 08-14-2025
- Dividend Yield
- VIVS N/A
- IDAI N/A
- EPS Growth
- VIVS N/A
- IDAI N/A
- EPS
- VIVS N/A
- IDAI N/A
- Revenue
- VIVS $142,000.00
- IDAI $3,366,415.00
- Revenue This Year
- VIVS $42.38
- IDAI $65.46
- Revenue Next Year
- VIVS $15.42
- IDAI $12.00
- P/E Ratio
- VIVS N/A
- IDAI N/A
- Revenue Growth
- VIVS 94.52
- IDAI N/A
- 52 Week Low
- VIVS $1.41
- IDAI $1.43
- 52 Week High
- VIVS $21.96
- IDAI $18.75
- Technical
- Relative Strength Index (RSI)
- VIVS N/A
- IDAI 45.91
- Support Level
- VIVS N/A
- IDAI $2.65
- Resistance Level
- VIVS N/A
- IDAI $3.16
- Average True Range (ATR)
- VIVS 0.00
- IDAI 0.19
- MACD
- VIVS 0.00
- IDAI -0.03
- Stochastic Oscillator
- VIVS 0.00
- IDAI 18.97
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.